Hepatitis C elimination among people who inject drugs in Mexico during the COVID-19 pandemic
article |attention |coronavirus disease 2019 |epidemic |health disparity |hepatitis C |Hepatitis C virus |human |Human immunodeficiency virus infection |injection drug user |Mexico |nonhuman |pandemic |prevention |South and Central America
; 2022(Gaceta Medica de Mexico)
Article
in Spanish
| WHO COVID | ID: covidwho-1884918
ABSTRACT
In 2019, Mexico was one of the first countries in Latin America to commit resources to achieve hepatitis C elimination by 2030. One year after this commitment, the global COVID-19 pandemic diverted attention to address immediate health needs to combat the spread of the disease. As a result, efforts to implement hepatitis C prevention and management programs were indefinitely postponed. Furthermore, populations at high risk of contracting the hepatitis C virus (HCV) and who bear the greatest burden of HCV national epidemic, including people who inject drugs and people who live with human immunodeficiency virus infection, remain exposed to extreme health disparities, which have potentially been exacerbated during the COVID-19 pandemic. In this article, we discuss the potential impact the COVID-19 pandemic has had on HCV elimination efforts in Mexico and the urgent need to resume them, since without these efforts, HCV elimination goals are likely not be achieved in the country by 2030.
Full text:
Available
Collection:
Databases of international organizations
Database:
WHO COVID
Type of study:
Prognostic study
Country/Region as subject:
Mexico
Language:
Spanish
Journal:
Article |attention |coronavirus disease 2019 |epidemic |health disparity |hepatitis C |Hepatitis C virus |human |Human immunodeficiency virus infection |injection drug user |Mexico |nonhuman |pandemic |prevention |South and Central America
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS